October 2, 2024

In October 2024, Alverno Laboratories announced two important updates. First, they are validating new CLSI tobramycin MIC breakpoints for Pseudomonas aeruginosa, which lower the susceptibility thresholds. This change will be implemented using Etest MIC methodology upon request. Second, effective November 14, 2024, Quest Diagnostics will discontinue the Listeria Antibody by Complement Fixation test, with no replacement offering available. These updates may impact diagnostic procedures in healthcare practices.